Quarterly Financial Information (unaudited) (Parenthetical) (Details) - Novartis [Member] - USD ($) $ in Millions |
3 Months Ended | 12 Months Ended | |
|---|---|---|---|
Sep. 30, 2017 |
Jun. 30, 2017 |
Dec. 31, 2017 |
|
| Error Corrections And Prior Period Adjustments Restatement [Line Items] | |||
| License fee revenue recognized | $ 35.4 | ||
| Collaborative Arrangement [Member] | |||
| Error Corrections And Prior Period Adjustments Restatement [Line Items] | |||
| Milestone received under the collaboration agreement | $ 10.0 | $ 10.0 | |
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Refers to the payment percentage of milestone received under the collaboration agreement. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|